Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
04 10 2023
Historique:
received: 24 10 2022
accepted: 06 09 2023
medline: 1 11 2023
pubmed: 5 10 2023
entrez: 4 10 2023
Statut: epublish

Résumé

Multivalent antigen display is a fast-growing area of interest toward broadly protective vaccines. Current nanoparticle-based vaccine candidates demonstrate the ability to confer antibody-mediated immunity against divergent strains of notably mutable viruses. In coronaviruses, this work is predominantly aimed at targeting conserved epitopes of the receptor binding domain. However, targeting conserved non-RBD epitopes could limit the potential for antigenic escape. To explore new potential targets, we engineered protein nanoparticles displaying coronavirus prefusion-stabilized spike (CoV_S-2P) trimers derived from MERS-CoV, SARS-CoV-1, SARS-CoV-2, hCoV-HKU1, and hCoV-OC43 and assessed their immunogenicity in female mice. Monotypic SARS-1 nanoparticles elicit cross-neutralizing antibodies against MERS-CoV and protect against MERS-CoV challenge. MERS and SARS nanoparticles elicit S1-focused antibodies, revealing a conserved site on the S N-terminal domain. Moreover, mosaic nanoparticles co-displaying distinct CoV_S-2P trimers elicit antibody responses to distant cross-group antigens and protect male and female mice against MERS-CoV challenge. Our findings will inform further efforts toward the development of pan-coronavirus vaccines.

Identifiants

pubmed: 37794071
doi: 10.1038/s41467-023-41661-4
pii: 10.1038/s41467-023-41661-4
pmc: PMC10551005
doi:

Substances chimiques

Antibodies, Viral 0
Epitopes 0
Vaccines 0
Spike Glycoprotein, Coronavirus 0
Antibodies, Neutralizing 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6195

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM136534
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2023. Springer Nature Limited.

Références

J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
Adv Virus Res. 2018;100:163-188
pubmed: 29551135
Front Immunol. 2020 Oct 07;11:576622
pubmed: 33117378
Nat Commun. 2019 Sep 19;10(1):4272
pubmed: 31537780
Elife. 2020 Aug 04;9:
pubmed: 32748788
Cell Rep. 2021 Nov 2;37(5):109929
pubmed: 34710354
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Front Immunol. 2021 Jul 12;12:701501
pubmed: 34322129
Cell. 2021 Oct 14;184(21):5432-5447.e16
pubmed: 34619077
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939
Science. 2021 Aug 27;373(6558):991-998
pubmed: 34214046
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Virology. 2018 Apr;517:98-107
pubmed: 29277291
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Cell Rep. 2019 Sep 24;28(13):3395-3405.e6
pubmed: 31553909
PLoS Pathog. 2020 Aug 11;16(8):e1008665
pubmed: 32780770
Cell Rep. 2022 Aug 30;40(9):111299
pubmed: 35988541
Nat Commun. 2021 Feb 9;12(1):883
pubmed: 33563988
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
Int J Biol Sci. 2020 Mar 15;16(10):1686-1697
pubmed: 32226286
N Engl J Med. 2022 Jan 27;386(4):297-299
pubmed: 34910863
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Nat Microbiol. 2016 Nov 28;2:16226
pubmed: 27892925
Nat Immunol. 2019 Mar;20(3):362-372
pubmed: 30742080
Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81
pubmed: 15474494
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Nature. 2021 Apr;592(7855):623-628
pubmed: 33762730
J Struct Biol. 1996 Jan-Feb;116(1):190-9
pubmed: 8742743
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701

Auteurs

Geoffrey B Hutchinson (GB)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Institute for Protein Design, University of Washington School of Medicine, Seattle, WA, USA.
Department of Immunology, University of Washington School of Medicine, Seattle, WA, USA.

Olubukola M Abiona (OM)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Case Western Reserve University, Cleveland, OH, USA.

Cynthia T Ziwawo (CT)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Anne P Werner (AP)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.

Daniel Ellis (D)

Institute for Protein Design, University of Washington School of Medicine, Seattle, WA, USA.
Department of Biochemistry, University of Washington School of Medicine, Seattle, WA, USA.

Yaroslav Tsybovsky (Y)

Vaccine Research Center Electron Microscopy Unit, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Sarah R Leist (SR)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Charis Palandjian (C)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Ande West (A)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Ethan J Fritch (EJ)

Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Nianshuang Wang (N)

College of Natural Sciences, University of Texas at Austin, Austin, USA.

Daniel Wrapp (D)

College of Natural Sciences, University of Texas at Austin, Austin, USA.

Seyhan Boyoglu-Barnum (S)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

George Ueda (G)

Institute for Protein Design, University of Washington School of Medicine, Seattle, WA, USA.
Department of Biochemistry, University of Washington School of Medicine, Seattle, WA, USA.

David Baker (D)

Institute for Protein Design, University of Washington School of Medicine, Seattle, WA, USA.
Department of Biochemistry, University of Washington School of Medicine, Seattle, WA, USA.
Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.

Masaru Kanekiyo (M)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Jason S McLellan (JS)

College of Natural Sciences, University of Texas at Austin, Austin, USA.

Ralph S Baric (RS)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Neil P King (NP)

Institute for Protein Design, University of Washington School of Medicine, Seattle, WA, USA.
Department of Biochemistry, University of Washington School of Medicine, Seattle, WA, USA.

Barney S Graham (BS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. bgraham@msm.edu.

Kizzmekia S Corbett-Helaire (KS)

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. kizzmekia_corbett@hsph.harvard.edu.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA. kizzmekia_corbett@hsph.harvard.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH